Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie

URN zum Zitieren dieses Dokuments:

urn:nbn:de:bvb:355-epub-408745 Copy

DOI zum Zitieren dieses Dokuments:

10.5283/epub.40874 Copy

Knoedler, M. ; Gauler, T. C. ; Gruenwald, V. ; Matzdorff, A. ; Schroeder, M. ; Dietz, A. ; Jordan, W.-O. ; Arnold, B. ; Hennemann, Burkhard ; Keilholz, Ulrich

Vorschau

PDF - Veröffentlichte Version (136kB)

Veröffentlichungsdatum dieses Volltextes: 21 Okt 2019 09:12

---

Alternative Links zum Volltext:DOIVerlag

---

---

Details

Dokumentenart:	Artikel
Open Access Art:	Allianz-/Nationallizenz
Titel eines Journals oder einer Zeitschrift:	Oncology
Verlag:	Karger
Band:	84
Seitenbereich:	S. 284-289
Datum:	2013
Zusätzliche Informationen (Öffentlich):	OA-Komponente aus Allianzlizenz
Institutionen:	Medizin > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Identifikationsnummer:	Wert Typ 10.1159/000345453 DOI
Stichwörter / Keywords:	Cetuximab, Disease control rate, Docetaxel, Platinum sensitivity, Squamous cell carcinoma of the head and neck
Dewey-Dezimal-Klassifikation:	600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
Status:	Veröffentlicht
Begutachtet:	Ja, diese Version wurde begutachtet
An der Universität Regensburg entstanden:	Ja
Dokumenten-ID:	40874

Vorschau

Bibliographische Daten exportieren

ASCII CitationAtomBibTeXData Cite XMLDataCite XML OAIDublin CoreDublin Core (LZV)EndNoteHTML CitationJSONJSON LDMETSMODSOPENAIREOpenAPCRDF+N-TriplesRDF+N3RDF+XMLReferReference ManagerSimple MetadataXMLopenCostxMetaDissPlus

---

Zusammenfassung

Background: Cetuximab and docetaxel have single-agent activity in squamous cell carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated in platinum-pretreated patients with recurrent and/or metastatic SCCHN. Patients and Methods: A total of 84 patients were treated with docetaxel 35 mg/m2 weekly for a maximum of 6 cycles and concomitant cetuximab 250 mg/m2 weekly ...

Zusammenfassung

Background: Cetuximab and docetaxel have single-agent activity in squamous cell carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated in platinum-pretreated patients with recurrent and/or metastatic SCCHN. Patients and Methods: A total of 84 patients were treated with docetaxel 35 mg/m2 weekly for a maximum of 6 cycles and concomitant cetuximab 250 mg/m2 weekly until disease progression or unacceptable toxicity. The primary endpoint was the objective response rate and secondary endpoints included the response rate in relation to platinum sensitivity, progression-free survival (PFS), overall survival (OS) and toxicity. Results: Nine (11%) patients achieved a partial response and 34 (40%) stable disease, resulting in a disease control rate of 51%. Response to treatment was 49% in previously platinum-sensitive and 50% in previously platinum-resistant disease. The median PFS was 3.1 months and the median OS 6.7 months. The most common grade 3 or 4 adverse events were mucositis (8%), pneumonia (8%), fatigue (8%) and skin reactions (14%). Sepsis occurred in 3 patients. Conclusion: Cetuximab plus docetaxel is an active treatment regimen with moderate toxicity in SCCHN patients. However, no superiority in comparison with monotherapy could be shown. Responsiveness and survival were independent of previous platinum sensitivity.

---

---

Metadaten zuletzt geändert: 10 Feb 2022 08:47

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Downloadstatistik

Downloadstatistik

Downloadstatistik

Downloadstatistik

Downloads

Downloads im Monat während des letzten Jahres

Altmetric

Altmetric

Altmetric

Alternative Statistik (altmetrics)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)